phytochlorin and Immune-System-Diseases

Drug targeting is an attractive new approach to killing cancer cells while leaving normal tissue unharmed. Recently we have developed a new generation of antibody-targeted immunosuppressive (cyclosporin A) and cytostatic (daunomycin, doxorubicin) drugs and photosensitizers (chlorin e6) effective in vitro and in vivo. The drugs and the targeting antibody (polyclonal and monoclonal) are conjugated to the oligopeptidic side chains of a water-soluble synthetic carrier, copolymer of N-(2-hydroxypropyl)methacrylamide. The composition of the side chains ensures the stability of the linkage between the drug and the polymeric carrier in the bloodstream and its intralysosomal degradability which is a prerequisite for the pharmacological activity of the preparation. Antibody-targeted polymer bound drugs show considerably decreased hepatotoxicity, cardiotoxicity, myelotoxicity and nephrotoxicity. Two adriamycin-HPMA copolymers are in Phase I/II clinical trials in United Kingdom.

Topics: Acrylamides; Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antineoplastic Agents; Chlorophyllides; Clinical Trials as Topic; Cyclosporine; Daunorubicin; Doxorubicin; Histocompatibility Antigens Class II; Humans; Immune System Diseases; Immunoconjugates; Immunosuppressive Agents; Lysosomes; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Polymethacrylic Acids; Porphyrins; Radiation-Sensitizing Agents; T-Lymphocyte Subsets; Thy-1 Antigens; Tissue Distribution